United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella  species, enterobacter  species, morganella morganii , proteus mirabilis  and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis med

United States - English - NLM (National Library of Medicine)

boiron - calendula officinalis flowering top (unii: 18e7415pxq) (calendula officinalis flowering top - unii:18e7415pxq) - - temporarily protects and helps promote healing of minor burns. do not use - over large areas of the body - if you are allergic to calendula officinalis or to this product's inactive ingredients. - under tight bandages. - do not use if glued carton end flaps are broken or if the tube seal is broken. calendula officinalis 1x hpus 4%... healing agent stop use and ask a doctor if condition persists for more than 3 days or worsens or reoccurs.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hcl injection, usp is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma - metastatic transitional cell bladder carcinoma - metastatic thyroid carcinoma - metastatic gastric carcinoma - metastatic bronchogenic carcinoma doxorubicin is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] - severe hepatic impairment (defined as child pugh class c or serum bilirubin level greater than 5 mg/dl) [see warnings and precautions (5.5)] - severe hypersensitivity reaction to doxorubicin including anaphylaxis [see adverse reactions (6.2)] pregnancy category d risk summary doxorubicin can cause fetal harm when administered to a pregnant woman. doxorubicin was teratogenic and embryotoxic in rats and rabbits at doses approximately 0.07 times (based on body surface area) the recommended human dose of 60 mg/m2 . if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus. animal data doxorubicin was teratogenic and embryotoxic at doses of 0.8 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) when administered during the period of organogenesis in rats. teratogenicity and embryotoxicity were also seen using discrete periods of treatment. the most susceptible was the 6- to 9-day gestation period at doses of 1.25 mg/kg/day and greater. characteristic malformations included esophageal and intestinal atresia, tracheo-esophageal fistula, hypoplasia of the urinary bladder, and cardiovascular anomalies. doxorubicin was embryotoxic (increase in embryofetal deaths) and abortifacient at 0.4 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) in rabbits when administered during the period of organogenesis. doxorubicin has been detected in the milk of at least one lactating patient [see clinical pharmacology (12.3)] . because of the potential for serious adverse reactions in nursing infants from doxorubicin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. based on postmarketing reports, pediatric patients treated with doxorubicin are at risk for developing late cardiovascular dysfunction. risk factors include young age at treatment (especially < 5 years), high cumulative doses and receipt of combined modality therapy. long-term periodic cardiovascular monitoring is recommended for all pediatric patients who have received doxorubicin. doxorubicin, as a component of intensive chemotherapy regimens administered to pediatric patients, may contribute to prepubertal growth failure and may also contribute to gonadal impairment, which is usually temporary. there are no recommended dose adjustments based on age. doxorubicin clearance was increased in patients aged 2 years to 20 years as compared to adults, while doxorubicin clearance was similar in children less than 2 years as compared to adults [see clinical pharmacology (12.3)]. clinical experience in patients who were 65 years of age and older who received doxorubicin based chemotherapy regimens for metastatic breast cancer showed no overall differences in safety and effectiveness compared with younger patients. contraception females doxorubicin can cause fetal harm when administered during pregnancy. advise female patients of reproductive potential to use highly effective contraception during treatment with doxorubicin and for 6 months after treatment. advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking doxorubicin [see use in specific populations (8.1)] . males doxorubicin may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. males with female sexual partners of reproductive potential should use effective contraception during and for 6 months after treatment [see nonclinical toxicology (13.1)] . infertility females in females of reproductive potential, doxorubicin may cause infertility and result in amenorrhea. premature menopause can occur. recovery of menses and ovulation is related to age at treatment [see nonclinical toxicology (13.1)] . males doxorubicin may result in oligospermia, azoospermia, and permanent loss of fertility. sperm counts have been reported to return to normal levels in some men. this may occur several years after the end of therapy. the clearance of doxorubicin was reduced in patients with elevated serum bilirubin levels. reduce the dose of doxorubicin in patients with serum bilirubin levels greater than 1.2 mg/dl [see dosage and administration (2.2) and warnings and precautions (5.5)] . doxorubicin is contraindicated in patients with severe hepatic impairment (defined as child pugh class c or serum bilirubin levels greater than 5 mg/dl) [see contraindications (4)] .

United States - English - NLM (National Library of Medicine)

personal care products - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - alcohol 146 ml in 236 ml - purpose: antiseptic uses - for hand washing to decrease bacteria on the skin - recommended for repeated use.

United States - English - NLM (National Library of Medicine)

homeolab usa inc - arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), hypericum perforatum (unii: xk4iux8mnb) (hypericum perforatum - unii:xk4iux8mnb) - arnica montana 1 [hp_x] in 50 g - pain, bruises, sprains, muscle aches bruises, strains these claims have not been reviewed by the food and drug administration. they are based on traditional homeopathic practice. this homeopathic medecine is made from a combination of ingredients traditionally used to help relieve symptoms associated with: - minor bruises - strains - sprains - muscle aches

United States - English - NLM (National Library of Medicine)

lannett company, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 1 mg in 1 ml - aripiprazole oral solution is indicated for the treatment of: - schizophrenia [see clinical studies (14.1 )] - acute treatment of manic and mixed episodes associated with bipolar i disorder [see clinical studies (14.2 )] - adjunctive treatment of major depressive disorder [see clinical studies (14.3 )] - irritability associated with autistic disorder [see clinical studies (14.4 )] - treatment of tourette’s disorder [see clinical studies (14.5 )] aripiprazole oral solution is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://wome

Canada - English - Health Canada

dolisos laboratoires s.a. - lycopus virginicus - tablet - 1dh - lycopus virginicus 1dh - homeopathic products

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

hikma pharmaceuticals plc - ibuprofen - tablet - 400 mg

Singapore - English - HSA (Health Sciences Authority)

boston scientific asia pacific pte. ltd. - cardiovascular - it is intended to provide a pathway to be used for delivering contrast media to selected sites in the vascular system during an angiographic procedure.

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - zinc cation 6.6 mg in 1 ml - multitrace ® - 4 neonatal is indicated for use as a supplement to intravenous solutions given for tpn. administration of multitrace ® - 4 neonatal in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace ® - 4 neonatal should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.